CorMedix Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical company commercializing DefenCath and a broader portfolio of institutional-care specialty pharmaceuticals. Form 8-K reports cover operating results, financial condition, corporate presentations, material-event disclosures, clinical or regulatory updates and business developments following the completed Melinta Therapeutics acquisition.
Proxy statements describe shareholder voting matters, board and governance practices, equity incentive plan proposals, certificate of incorporation matters and preferred-stock voting provisions. Acquisition-related amendments include financial statements of the acquired business and pro forma financial information, while the company’s securities disclosures identify CRMD common stock listed on the Nasdaq Global Market.
CorMedix Inc. Chief Operating Officer Elizabeth Hurlburt reported equity compensation and a related share sale. On 01/23/2026 she received 93,010 shares of common stock for $0.00 per share as a grant of restricted stock units that convert into common stock.
The restricted stock units vest 1/4 at grant and, subject to continued employment, 1/4 on each of the first, second, and third anniversaries of the grant date. On the same day, 10,778 shares of common stock were disposed of at $7.27 per share, typically reflecting shares withheld or sold to cover taxes, leaving her with 242,533 directly owned shares.
CorMedix Inc.’s Chief Executive Officer and director Joseph Todisco reported an equity award and related share transaction. On 01/23/2026, he received 225,900 restricted stock units, each representing one share of common stock, at a price of $0.00.
The restricted stock units vest 1/4 on the grant date and, subject to continued employment, 1/4 on each of the first, second, and third anniversaries of the grant. On the same date, a second transaction labeled code F covered 27,306 shares at $7.27 per share, leaving Todisco with 697,593 common shares held directly.
CorMedix Inc. director Myron Kaplan received an equity grant of 30,453 restricted stock units on January 26, 2026. The Form 4 shows these RSUs were awarded at a price of $0.00 per unit and will vest in full on January 26, 2027, subject to his continued service through that date.
Following this grant, Kaplan directly beneficially owned 231,487 shares of CorMedix common stock. The filing also notes additional indirect holdings of 20,000 shares held by his spouse and 10,000 shares held by his spouse as guardian for grandchildren, for which he expressly disclaims beneficial ownership.
CorMedix Inc. director Janet Dillione received an equity grant of 30,453 shares of common stock in the form of restricted stock units. The units were issued on January 26, 2026 at a stated price of $0.00 per share and represent a right to receive an equal number of common shares.
The restricted stock units will vest in full on January 26, 2027, conditioned on continued service through that date. Following this grant, Dillione beneficially owns 68,926 shares of CorMedix common stock in direct ownership.
CorMedix Inc. director Steven W. Lefkowitz reported receiving 30,453 shares of common stock on January 26, 2026 as restricted stock units granted at $0.00 per share. These units each represent one share of common stock and will vest in full on January 26, 2027, subject to his continued service.
After this grant, he beneficially owns 125,951 shares directly. He also has indirect beneficial ownership of 30,152 shares through the Wade Capital Corporation Money Purchase Plan, where he has voting and investment control, and 2,000 shares held by his spouse.
CorMedix Inc. director Alan W. Dunton received an equity award in the form of restricted stock units. On January 26, 2026, he was granted 30,453 restricted stock units of CorMedix common stock at a grant price of $0.00 per unit, increasing his beneficial ownership to 70,703 shares.
Each restricted stock unit represents the right to receive one share of common stock. The units will vest in full on January 26, 2027, provided he continues serving the company through the vesting date.
CorMedix Inc. director Duncan Gregory Scott received a grant of 30,453 restricted stock units (RSUs) of common stock on January 26, 2026. The RSUs were awarded at a price of $0.00 per unit, reflecting an equity compensation grant rather than a market purchase.
Each RSU represents the right to receive one share of CorMedix common stock. The RSUs will vest in full on January 26, 2027, provided Scott continues his service through the vesting date. After this grant, he beneficially owns 68,786 shares of CorMedix common stock in direct ownership form.
CorMedix Inc. director Stewart Robert A reported receiving 30,453 shares of common stock on a restricted basis at a price of $0.00 per share. Following this grant, he beneficially owns 66,453 CorMedix shares directly.
The award consists of restricted stock units issued on January 26, 2026. Each unit converts into one share of common stock and will vest in full on January 26, 2027, provided he continues to serve through the vesting date.
CorMedix Inc. director Janet Dillione reported a sale of company stock. On January 21, 2026, she sold 10,000 shares of CorMedix common stock at a weighted average price of $6.88 per share, in multiple trades executed between $6.85 and $6.90 per share. After this transaction, she beneficially owned 38,473 shares of CorMedix common stock directly.
The filing notes that the reported price is an average across several individual trades, and the director has agreed to provide detailed trade and pricing information to regulators, the company, or any security holder who requests it.
A person associated with CRMD has filed a notice to sell common stock under Rule 144. The filing shows a planned sale of 10,000 common shares through Merrill Lynch, with an aggregate market value of 68,502, on or about 01/21/2026 on the NASDAQ. The issuer had 78,789,045 shares of common stock outstanding. The seller acquired these 10,000 shares on 01/17/2026 via stock plan activity.
Over the prior three months, the same seller completed additional sales of common stock, including 34,000 shares for 407,030 on 12/09/2025, 46,657 shares for 465,169 on 12/02/2025, and 26,343 shares for 260,805 on 11/24/2025. This Form 144 is a notice of intent and does not by itself confirm that the planned shares have been sold.